TRILIO
17.5.2022 13:08:04 CEST | Business Wire | Press release
KUBECON + CLOUDNATIVECON EUROPE— Trilio , a leading provider of cloud-native data protection, today announced a technical preview of a new “Continuous Restore” capability that is being showcased to the cloud-native community at the KubeCon + CloudNativeCon Europe conference. Continuous Restore offers faster levels of replication, restoration and migration of data and metadata from any storage or cloud platform to another, dramatically improving recovery times for cloud-native applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005514/en/
Entirely storage-, cloud- and distribution-agnostic, Trilio’s “Continuous Restore” capability will enable users to continuously stage data at multiple and heterogeneous clouds. This means that applications—regardless of where they reside—will be able to tap into that data and be brought online in seconds, achieving exceptional levels of Recovery Time Objectives (RTO). The capability will be introduced as part of the TrilioVault for Kubernetes cloud-native data protection and management platform.
“Distributed environments consisting of core, edge and cloud resources are becoming the predominant architecture for enterprises today,” said Murali Balcha, Founder and CTO of Trilio. “Companies frequently need to move stateful applications and their data volumes among these diverse environments to achieve cost-efficiency, performance, security and disaster recovery imperatives. Unfortunately, no easy-to-use, affordable solution for continuous data volume replication across heterogeneous infrastructure environments exists today.”
“Trilio’s Continuous Restore capability enables migration and replication of stateful applications in seconds or minutes so that all companies can protect and use their data anywhere—regardless of what the application runs on or where the data is stored,” continued Balcha. “This provides organizations the ability to meet leading levels of application uptime, achieve Service Level Agreements (SLAs) expected of production-grade applications—all at an affordable cost. Continuous Restore is a game-changer that will make today’s modern businesses even more competitive and resilient.”
***To see a Demo of Continuous Restore, visit Trilio at Booth P11 at KubeCon + CloudNativeCon Europe or schedule a meeting with our K8s Experts ***
Use cases for the Continuous Restore capability include:
1. Disaster Recovery: Users will be able to achieve availability objectives and recover from outages or failures in a matter of seconds or minutes rather than days or weeks. Using Continuous Restore, Recovery Time Objectives (RTO) will improve by over 80% versus traditional methods.
2. Application Migrations : Continuous Restore allows IT teams to optimize performance and achieve better Total Cost of Ownership (TCO) by choosing the infrastructure best suited to current needs. The Continuous Restore capability will also enable organizations to unify their infrastructure, especially those that have grown quickly and adopted a variety of compute platforms and storage solutions to meet unique needs. Continuous Restore will make possible tremendously fast application mobility across infrastructure silos, making them silos no more.
3. Testing/Development: Developers can increase the velocity of CI/CD pipelines by staging data for multiple test/dev environments. These test/dev environments can be spun up in seconds with continuously replicated production data and accelerating the push of validated changes into production. In fact, DevOps teams can use this capability to test their “restore” protocols to ensure that restore will work when needed.
4. Data Curation from Edge Clouds: As distributed environments proliferate in the future, massive amounts of data will be collected at “the edge,” and this information from diverse architectures will need to be rapidly replicated and moved throughout distributed systems where it can be assimilated and centrally analyzed by any number of different applications.
Attend Trilio’s Session: “ Cloud-Native App Recoverability & Portability in a Matter of Seconds thru the Unification of Information Silos'' on Thursday May 19 3pm CET at the Microsoft Azure Booth P12. Join Ben Morrison, solution architect at Trilio, for his presentation and demo showcasing Trilio's capability for migrating a stateful application from on-prem Red Hat OpenShift to Azure AKS in a matter of seconds — highlighting the flexibility and speed enabled by the TrilioVault for Kubernetes platform.
Continuous Restore is a capability within TrilioVault for Kubernetes and will be made generally available as part of a product release in Q3’22. For those that want to preview or test the capability, please contact Trilio .
About Trilio
Trilio is a leader in cloud-native data protection for Kubernetes, OpenStack and Red Hat Virtualization environments. Our TrilioVault technology is trusted by cloud infrastructure operators and developers for backup and recovery, migration and application mobility. Customers in telecom, defense, automotive and financial services leverage TrilioVault to recover from disasters, migrate workloads, move workloads to new infrastructure and migrate to new software distributions. Trilio.io , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005514/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom